Know Cancer

forgot password

Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Phase 3
18 Years
Not Enrolling
Non-Small Cell Lung Cancer

Thank you

Trial Information

Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Inclusion Criteria

Inclusion criteria:

- Informed consent

- Histologically confirmed diagnosis of NSCLC, non epidermoid, stage IV or IIIB with
pleural effusion, or N3 tumours not candidate for thoracic radiotherapy, harbouring
deletions in the exon 19 or mutation in the exon 21 in the TK of the EGFR.

- Either measurable or evaluable disease.

- Age > 18 years.

- ECOG performance status < 2.

- Adequate bone marrow function

- Adequate renal function

- Adequate hepatic function

- Patients must be accessible for treatment and follow-up.

- Patients capable of following an adequate therapeutic compliance

- Women of child bearing potential: negative pregnancy test.

- Patients of both genders at a fertile age, including those women having their last
menstruation within the two previous years, must follow effective contraceptive

- Ability to swallow.

- Patients with asymptomatic brain metastasis and stable with medical treatment will be
eligible for the study. Patients having received radiotherapy for their brain
metastasis prior to the systemic treatment for the NSCLC will be also eligible.

- Absence of gastrointestinal tract problems

Exclusion criteria:

- Pregnant or lactating women.

- Women of child bearing potential having a positive pregnancy test in the basal visit
or not accomplishing the test.

- Patients of both genders sexually active (at a fertile age) not following
contraceptive measures during the study.

- Prior chemotherapy for metastatic disease. Both prior neoadjuvant and adjuvant
chemotherapy allowed provided that completed ≥ 6 months before entering the study.

- Prior treatment with EGFR targeted therapies.

- Patients may have received radiotherapy, provided that the irradiated lesion is not
the only evaluable lesion for response and completed before entering the study.

- Prior experimental pharmacological agent within the 3 weeks prior to the inclusion of
the study.

- Any significant ophthalmologic impairment of the eye surface. Use of contact lenses
is not recommended.

- Pre-existing motor or sensorial neurotoxicity grade > 2, according to the NCI-CTC

- Evidence of spinal cord compression.

- Inability to take oral medication and surgical procedures affecting the absorption or
implying intravenous or parenteral feeding.

- Any other severe disease or clinical conditions, as, but not only:

- Unstable cardiopathy despite treatment, myocardial infarction within the 6
months before entering the study

- History of significant neurological or psychiatric disorders, including dementia
and epileptic seizures.

- Uncontrolled active infection.

- Uncontrolled peptic ulcer.

- Unstable diabetes mellitus or any other contraindication for treatment with

- AST and/or ALT > 1.5 x UNL associated to alkaline phosphatase > 2.5 x UNL.

- Any other underlying severe process affecting the ability to take part in the

- Absolute contraindication for steroids.

- Dementia or significant mental disorder interfering the understanding and giving the
informed consent.

- History of other malignancy except adequately treated basal cell or squamous cell
skin cancer, carcinoma in situ of the cervix, radically treated prostatic carcinoma
with good prognostic (Gleason = 6). History of other curatively treated malignancy
and no evidence of disease within the past 5 years.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free-survival

Outcome Time Frame:

Every 6 weeks

Principal Investigator

Rafael Rosell i Costa, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Spanish Lung Cancer Group


Spain: Spanish Agency of Medicines

Study ID:




Start Date:

February 2007

Completion Date:

December 2012

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Lung
  • cancer
  • EGFR
  • Epidermal Growth Factor Receptor
  • tyrosine kinase
  • Tarceva®
  • Erlotinib
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms